Digital Transformation and Financing Costs for Chinese Pharmaceutical Firms, 2016–2023

From 2016 to 2023, this dataset comprises 1,216 observations from 152 A-share listed pharmaceutical manufacturing companies in China. It was created by Jingdong Huang to analyze the impact of digital transformation on financing costs through green certification and green finance. The data supports econometric models including fixed-effects panel regression, Bootstrap mediation tests, and instrumental variable methods.

Use Cases

• Modeling the relationship between digital transformation and financing costs based on panel data.
• Analyzing the mediating role of green certification and green finance availability as described in the study.
• Investigating heterogeneous effects between essential and non-essential drug enterprises on cost reduction.
• Testing mechanisms like information asymmetry mitigation and risk premium reduction mentioned in the results.

Strengths

• 1,216 observations provide a substantial sample for analysis.
• Data covers an 8-year period from 2016 to 2023.
• Study employs multiple econometric methods (fixed-effects, Bootstrap, IV, PSM-DID) to control for endogeneity.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 13.6 KB, suggesting limited scope or summary-level data.

Provenance

Source

Jingdong Huang via figshare.

Collection Method

Likely compiled from financial reports and corporate disclosures of A-share listed pharmaceutical companies.

Time Range

2016–2023

Freshness

Last updated 2026-05-15 05:41:08; freshness should be verified.

Geography

China